. home.aspx


Q&A: A Startup Scouring The Metabolome for Precision Medicine Biomarkers

January 30, 2020 / MATTHEW ARNOLD

Dr. O’Day: I think we’re actually on the cusp of making precision medicine real. The term’s been around for quite some time and I think we might have gotten a little ahead of ourselves because we saw a technology that could have impact. And over the past 5, 10 years we’ve been working to perfect that. You know, it’s all about getting the right drug to the right patient at the right time. We’ve made some strides there, primarily based on genomics profiling and stratifying patients based on different genetic mutations and risk groups, and then treating people accordingly. But we now have the ability to take that even further, to go end-to-end. Based on your molecular profile, we can say: here are the diseases you’re most likely to get, and we can monitor for them, and then if you co develop these diseases, we can tailor your treatment protocol for optimal outcomes. I think in the next ten years, what we all think of precision medicine as will actually become a reality.